eO was initially formed in 1997 to address the expected market for transaction based electronic commerce, principally in the mortgage and financial services markets. The company is a pioneer in electronic signature and post-sign trusted vaulting processes and actively participated in the early enabling federal and states model legislation. Many firsts, in this area of ecommerce, are attributable to the company: first fully paperless international trade transactions (Rabobank), first fully paperless leases (General Electric), first fully paperless mortgages (Fannie Mae), first securitization of digital financial instruments (Nissan Motor Credit), first commercial eVault software system, first eContracts collateral and control system for banks (Wells Fargo) . The company, in which a Concorde private equity partnership is the majority and controlling shareholder, was reconstituted and recapped after the dot.com bust and since that restart under a holding company, Paperless Transaction Management Corporation. The company has staked out a leadership position in the paperless business processes world of digital transaction management (DTM). With partners like Adobe and customers such as Tesla, Harley Davidson, FedEx, Dealer Track, and Bank of America, the company is experiencing a rapid growth rate beginning in 2011 and enjoys prominent recognition as the thought leader and gold-standard for the provision of vaulting and DTM capabilities in the market. A member of Concorde’s private equity portfolio management serves as Executive Chairman.
International Hospital Corporation Holding N.V. (IHH)
IHH was formed in 2006 with the roll-up of three sister Latin American based hospital companies, all of which were founded as start-ups in the period 1995-2006. The sister companies designed and built 3 and acquired 5 acute care hospitals in Mexico, Brazil and Costa Rica and managed them under the standards of “first world” quality and patent safety standards. From inception thru 2011 the company grew to 8 operating facilities with formal affiliations with some of the most recognized healthcare institutions in the US such as UT Southwestern, Baylor University Medical Center, Mayo clinic, Harvard, UCLA and others. Four of the company’s hospitals were US joint Commission accredited (Mexico and Central America) and four had other international accreditations (Brazil), at a time when less than 1% of hospitals worldwide outside the US had such accreditations. As a result of difficult capital formation markets resulting from the Great Recession, the company elected to reduce its operating platform and narrow the scope of operations and growth plans to fit within available capital resources. The company sold its Mexico division in 2013 to a large Mexican private hospital operator and currently is divesting the Brazil division in 2015. The company, which has 2 remaining hospitals in Costa Rica, is planning expansion through an acquisition strategy in Central America. A member of Concorde’s private equity portfolio management serves as Executive Chairman.
Klaris Diagnostics is a privately-held in vitro diagnostics company founded in 2016 to help hospitals combat the problem of antibiotic resistance. With the rise of multi-drug-resistant bacteria, there is an urgent need for solutions that will allow hospitals to safely cure and prevent antibiotic-resistant infections. Klaris has developed a groundbreaking technology that addresses this problem. Klaris’s next-generation clinical microbiology platform is based on its patented phenotypic single-cell technology that can rapidly identify pathogens and determine their antibiotic response without the need for traditional time-consuming culture steps. The result is life-saving antibiotic treatment information up to four days faster compared to the standard of care. A member of Omnimed Capital (a Concorde company) serves on the Klaris Board of Directors.
Nano-Signature Imaging Technologies (NSI)
NSI was formed in 2012 to commercialize an innovative remote sensing and imaging technology used in oil and gas exploration. A Concorde private equity partnership, which owns a minority interest, was a founding partner of NSI, contributing other oil and gas interests and cash in two tranches. Concorde is the largest outside non-management investor and serves in the capacity of the lead shareholder. The company altered its business plan from being primarily an intellectual property licensing revenue model, mixed with some hydrocarbon exploration, to an almost all hydrocarbon exploration model. In Late 2014, the company commenced initial exploration activities and the calibration of its technology to the specific basins in Southern Appalachia.
Special Purpose Limited Partnerships (SPLPs)
SPLPs have been formed throughout Concorde’s existence, like the currently active Concorde Tangible Assets Partners (CTAP), to provide for smaller individual capital allocations from accredited and qualified investors to be pooled so that the respective partnerships could meet minimum requirements for third party sponsored private equity opportunities. These partnerships, which predominantly take passive investment positions, are in addition to specific companies or investments, in which Concorde private equity management has taken active roles in the founding or in operations and governance. These smaller limited partnerships, where Concorde serves as the Managing general partner, have been formed to provide the vehicle for the pooling of smaller investment capital amounts from investors that have limited capital allocations available for private equity. These partnerships typically acquire investment positions with a specified purpose such as the tangible assets theme of CTAP. Specific portfolio holdings can be stock, debt or partnership participations in vertical market enterprises which historically have included oil and natural gas exploration, livestock, toys, manufacturing, hotel operations, information technology, commodities and precious metals.